Shining a light on rare cancers: The power of partnership for patients

June 26, 2025

Icon Cancer Centre logo

This Rare Cancers Awareness Day, Icon Cancer Centre is proud to spotlight the impact of their national partnership with Rare Cancers Australia (RCA), uniting RCA’s advocacy with Icon’s 45 centres and more than 300 doctors across Australia.

Together, we’re bridging critical gaps in care for patients facing rare and less common cancers.

Patients with a rare cancer often describe their journey as isolating and uncertain, with delayed diagnoses and fragmented support. For those in regional or outer metro areas, these challenges are compounded by long travel times and limited access to trials and specialist care.

Through this partnership, patients are gaining faster, more direct connection to the vital services RCA provides.

Icon is advancing innovation through its national research program, and partnership with Omico, helping bring genomic-enabled clinical trials closer to home.

Access to comprehensive genomic profiling is enabling faster, more accurate diagnoses and driving a major shift towards personalised treatment plans.

By generating the real-world evidence needed to support this approach, we’re working to embed personalised care into the standard cancer treatment pathway, ensuring innovation reaches every patient.

As Australia’s largest dedicated cancer care provider, Icon Cancer Centre delivers integrated services across medical oncology, haematology, radiation oncology, research and theranostics.

With 30% of centres in regional areas and 50% in outer-metro and regional communities, Icon is committed to delivering care closer to home.

Icon is also focused on driving lasting change by advocating for equitable access, sustainable funding models, and personalised treatment for every patient, no matter how rare their diagnosis or where they live.

Keep up with Rare Cancers Australia

Inside Rare is a monthly newsletter that shares the latest news, events and stories connecting the rare community.